4-amino-1-(4-bromo-3-ethoxyphenyl)-1H-pyrazole-3-carboxamide | 850727-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-amino-1-(4-bromo-3-ethoxyphenyl)-1H-pyrazole-3-carboxamide
• 英文别名: 4-Amino-1-(4-bromo-3-ethoxyphenyl)pyrazole-3-carboxamide
• CAS: 850727-48-9
• 化学式: C₁₂H₁₃BrN₄O₂
• 分子量: 325.165
• InChiKey: WQLVROWMWZZULK-UHFFFAOYSA-N

物化性质

• 沸点：
  484.6±45.0 °C(Predicted)
• 密度：
  1.68±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  96.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  potassium cyanate 、 4-amino-1-(4-bromo-3-ethoxyphenyl)-1H-pyrazole-3-carboxamide 在 溶剂黄146 作用下， 以 水 、 异丙醇 为溶剂， 反应 16.0h， 生成 4-[(aminocarbonyl)amino]-1-(4-bromo-3-ethoxyphenyl)-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
  [FR] COMPOSES D'UREE DE PYRAZOLE SUBSTITUEE UTILES DANS LE TRAITEMENT D'INFLAMMATIONS

  摘要：

  公式（I）的化合物：其中X1、X2、L1、A、R、L2、R1、R2、R2a、R3、R4和R4a如本文所定义，已被披露。

  公开号：

  WO2005037797A1
• 作为产物：
  描述：

  4-amino-3-(aminocarbonyl)-1-(4-bromo-3-ethoxyphenyl)-1H-pyrazole-5-carboxylic acid potassium salt 在 磷酸 作用下， 以 水 为溶剂， 反应 2.0h， 生成 4-amino-1-(4-bromo-3-ethoxyphenyl)-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
  [FR] COMPOSES D'UREE DE PYRAZOLE SUBSTITUEE UTILES DANS LE TRAITEMENT D'INFLAMMATIONS

  摘要：

  公式（I）的化合物：其中X1、X2、L1、A、R、L2、R1、R2、R2a、R3、R4和R4a如本文所定义，已被披露。

  公开号：

  WO2005037797A1

文献信息

• Substituted pyrazole urea compounds for the treatment of inflammation
  申请人：Huang He

  公开号：US20050197338A1

  公开（公告）日：2005-09-08

  Compounds of Formula I: wherein X 1 , X 2 , L 1 , A, R, L 2 , R 1 , R 12 , R 12a , R 13 , R 14 and R 14a are as defined herein, are disclosed.

  公式I的化合物：其中X1，X2，L1，A，R，L2，R1，R12，R12a，R13，R14和R14a如此定义，已被披露。
• [EN] SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY<br/>[FR] IMIDAZO[1,2-A]PYRAZINES SUBSTITUEES UTILISEES COMME MODULATEURS DE L'ACTIVITE D'UNE KINASE
  申请人：CELLULAR GENOMICS INC

  公开号：WO2005019220A2

  公开（公告）日：2005-03-03

  Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically-acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound of the invention to decrease the symptoms or slow the progression of these diseases or disorders. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with a compound of Formula I under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.